Heart rate and adverse outcomes in patients with prevalent atrial fibrillation

Autor: Steffen Blum, Stefanie Aeschbacher, David Conen, Stefan Osswald, Manuel R Blum, Michael Kuhne, Alberto Pagnamenta, Linda S B Johnson, Nicolas Rodondi, Richard Kobza, Giorgio Moschovitis, Christine S Zuern, Marcello Di Valentino, Maria Luisa De Perna, Patrizia Assunta Mayer Melchiorre, Alexander P Benz, Angelo Auricchio, Giulio Conte, Juerg H Beer

Publikováno v: Open Heart, Vol 8, Iss 1 (2021)

Objective The optimal target heart rate in patients with prevalent atrial fibrillation (AF) is not well defined. The aim of this study was to analyse the associations between heart rate and adverse outcomes in a large contemporary cohort of patients

Externí odkaz: https://doaj.org/article/b51d0ccf8f134e2b9a2f82579990be34

Oral factor Xa inhibitors for stroke prevention in patients with device-detected atrial fibrillation – Recent evidence from the NOAH-AFNET 6 and ARTESiA trials

Autor: Alexander P. Benz, William F. McIntyre

Publikováno v: Cardiologia Hungarica, Vol 54, Iss 2, Pp 90-91 (2024)

Device-detected atrial fibrillation (AF), also known as atrial high rate episodes, is a frequent finding in patients with a cardiac implantable electronic device such as a pacemaker, or an implantable cardioverter-defibrillator or loop recorder.

Externí odkaz: https://doaj.org/article/456beabc11044ef8adfdd2f6a7e8a36f

Biomarkers of Inflammation and Risk of Hospitalization for Heart Failure in Patients With Atrial Fibrillation

Autor: Alexander P. Benz, Stefanie Aeschbacher, Philipp Krisai, Giorgio Moschovitis, Steffen Blum, Pascal Meyre, Manuel R. Blum, Nicolas Rodondi, Marcello Di Valentino, Richard Kobza, Maria Luisa De Perna, Leo H. Bonati, Jürg H. Beer, Michael Kühne, Stefan Osswald, David Conen

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 8 (2021)

Background Hospitalization for heart failure (HF) is very common in patients with atrial fibrillation (AF). We hypothesized that biomarkers of inflammation can identify patients with AF at increased risk of this important complication. Methods and Re

Externí odkaz: https://doaj.org/article/4b41fec517334da981e73815bcc9a0cc

Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke

Autor: William F McIntyre, Jia Wang, Alexander P Benz, Linda Johnson, Stuart J Connolly, Isabelle C Van Gelder, Renato D Lopes, Michael R Gold, Stefan H Hohnloser, Chu Pak Lau, Carsten W Israel, Jorge A Wong, David Conen, Jeff S Healey

Publikováno v: Europace, 24(7), 1058-1064. Oxford University Press

Aims There is uncertainty about whether and how to perform screening for atrial fibrillation (AF). To estimate the incidence of previously undetected AF that would be captured using a continuous 14-day ECG monitor and the associated risk of stroke. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7baea995541219d4657c35b90addee3e
https://hdl.handle.net/11370/ca9536e1-01db-4a9c-87d0-b25c8e2d04b1

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban

Autor: Alexander P, Benz, Lizhen, Xu, John W, Eikelboom, Saskia, Middeldorp, Truman J, Milling, Mark, Crowther, Patrick, Yue, Pamela, Conley, Genmin, Lu, Stuart J, Connolly

Publikováno v: Thrombosis and Haemostasis, 122, 998-1005
Thrombosis and Haemostasis, 122, 6, pp. 998-1005
Thrombosis and haemostasis, 122(6), 998-1005. Schattauer GmbH

Background Andexanet alfa (andexanet) is approved for specific anticoagulation reversal in patients with life-threatening or uncontrolled bleeding during treatment with rivaroxaban or apixaban. There is limited experience with andexanet in patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b62a6eac18ed9bc2d57aeaf5c5f0b05
https://hdl.handle.net/2066/282358